KRAS and familial pancreatic carcinoma: Over the past decade, increasing evidences have shown that EVs of different types of cell origin can deliver different siRNA (such as KRAS (Kamerkar et al., 2017), surviving (Pi et al., 2018; Zhupanyn et al., 2020), KSP (Aqil et al., 2019), S100A4 (Zhao et al., 2020), PLK-1 (Greco et al., 2016), BCR-ABL (Bellavia et al., 2017), etc) to treat various tumor diseases (including pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, breast cancer, bladder cancer, and chronic myelogenous leukemia, etc.).